Author:
Biswas Ghanashyam,Subudhi Ganesh C,Biswas Sutapa,Das Bharat
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Breast cancer. Accessed. June 12, 2024: https://www.who.int/news-room/fact-sheets/detail/breast-cancer.
2. Efficacy and safety of trastuzumab emtansine plus capecitabine vs trastuzumab emtansine alone in patients with previously treated ERBB2 (HER2)-positive metastatic breast cancer: a Phase 1 and randomized phase 2 trial;Cortés J;JAMA Oncol,2020
3. T-DM1 for advanced breast cancer after multi-anti-HER2-target therapy: a case report;Sun L;Transl Breast Cancer Res,2021
4. Comparison of the efficacy, safety, pharmacokinetic and immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) with the Kadcyla (Trastuzumab Emtansine) in the treatment of HER2-positive metastatic breast cancer: a randomized, open-label, multicenter study in India;Chiradoni Thungappa S;Clin Breast Cancer,2022
5. Efficacy and safety of combined trastuzumab and paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience;Furukawa K;Breast Cancer,2006